Table 1 Clinical, pathologic and treatment related characteristics
ALL | |
|---|---|
n = 38 | |
Age, years | 62,9 ± 7,2 |
Preoperative PSA, ng/mL | 7,4 [9,8] |
Pathologic T stage | |
T2 | 25 (65,8) |
T3 | 13 (34,2) |
Pathologic N stage | |
N0 | 16 (42,1) |
Nx | 22 (57,9) |
Pathologic Gleason score | |
≤ 7 | 28 (73,7) |
> 7 | 10 (26,3) |
Positive surgical margin | |
Yes | 16 (42,1) |
No | 22 (57,9) |
Perineural Invasion | |
Yes | 17 (44,7) |
No | 21 (55,3) |
Lymphatic vessel invasion | |
Yes | 4 (10,5) |
No | 34 (89,5) |
PSA levels, ng/mL | |
Post radical prostatectomy | 0,1 [0,3] |
On day of biochemical failure | 0,4 [0,7] |
On day of choline PET/CT and mpMRI | 0,9 [1,8] |
Lowest PSA level after surgery | 0,1 [0.3] |
Treatment before mpMRI/choline PET/CT | |
Radical prostatetcomy only | 27 (71,1) |
Radical prostatectomy and hormonotherapy | 4 (10,5) |
Radical prostatectomy and radiotherapy | 7 (18,4) |
Time from prostatectomy, months | |
To first PSA recurrence | 10,5 [22,3] |
To mpMRI/PET/CT | 27,5 [54,0] |
PSA doubling time, months | 4,5 [8,3] |